financetom
Business
financetom
/
Business
/
Why Allbirds (BIRD) Stock Is Trading Lower
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Allbirds (BIRD) Stock Is Trading Lower
Sep 1, 2024 1:23 AM

Allbirds Inc ( BIRD ) shares are trading lower by 4.4% to 68 cents during Friday’s session after the company announced it will implement a 1-for-20 reverse stock split of its Class A and Class B Common Stock, following approval from its Board of Directors and stockholders.

The split, intended to help the company meet Nasdaq’s minimum bid price requirement, will take effect on September 4, 2024, with the stock trading on a split-adjusted basis starting September 5.

The reverse stock split will combine every 20 shares of Allbirds’ Common Stock into 1 share, with stockholders retaining the same ownership percentage post-split. No fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares.

Read Also: Fed’s Preferred Inflation Gauge Falls Short Of Expectations In July, Personal Spending Accelerates

Should I Sell My BIRD Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of Allbirds ( BIRD ) have decreased by 47.98% in the past year. An investor who bought shares of Allbirds ( BIRD ) at the beginning of the year would take a loss of $0.62 per share if they sold it today. The stock has risen 9.11% over the past month, meaning an investor who bought shares on Jul. 1 would see a capital gain of $0.2.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

According to data from Benzinga Pro, BIRD has a 52-week high of $1.46 and a 52-week low of $0.45.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Broadridge Financial Solutions Insider Sold Shares Worth $501,007, According to a Recent SEC Filing
Broadridge Financial Solutions Insider Sold Shares Worth $501,007, According to a Recent SEC Filing
May 21, 2024
02:32 PM EDT, 05/21/2024 (MT Newswires) -- Thomas P Carey, Corporate Vice President, on May 20, 2024, sold 2,500 shares in Broadridge Financial Solutions ( BR ) for $501,007. Following the Form 4 filing with the SEC, Carey has control over a total of 9,361 shares of the company, with 9,361 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1383312/000122520824006278/xslF345X03/doc4.xml Price: 199.34, Change:...
US airlines call for swift action in air traffic hiring
US airlines call for swift action in air traffic hiring
May 21, 2024
WASHINGTON, May 21 (Reuters) - The trade group representing major U.S. airlines on Tuesday urged the Federal Aviation Administration to take swift action to address a long-standing air traffic controller shortage ahead of the start of the busy summer travel season. Airlines for America, whose members includes American Airlines ( AAL ), Delta Air Lines ( DAL ), United Airlines...
US Steel Accuses Cleveland-Cliffs of Running
US Steel Accuses Cleveland-Cliffs of Running "Misinformation Campaign" Against Nippon Steel Deal
May 21, 2024
02:35 PM EDT, 05/21/2024 (MT Newswires) -- United States Steel ( X ) on Tuesday accused Cleveland-Cliffs ( CLF ) of running a misinformation campaign against the steelmaker's deal with Japan's Nippon Steel. The investment by [Nippon Steel] has been under attack since day one by one of our competitors and unsuccessful bidder -- Cleveland-Cliffs ( CLF ) -- who...
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
May 21, 2024
Tuesday, the FDA's staff reviewers raised concerns regarding Guardant Health Inc's ( GH ) experimental blood test for colorectal cancer, suggesting it might not detect some tumor types that could become cancerous.  Guardant Health ( GH ) is seeking approval for Shield, a blood-based colorectal cancer (CRC) screening test for average-risk adults.  Shield is an in vitro diagnostic device intended for the qualitative detection of CRC through sequencing the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved